Alpha- Antitrypsin Deficiency (AATD) – Market Insights, Epidemiology and Market Forecast-2023

DelveInsight’s ‘Alpha Antitrypsin Deficiency – Market Insights, Epidemiology, and Market Forecast-2023’ report provides an overview of the Alpha Antitrypsin Deficiency and global market size of the Alpha Antitrypsin Deficiency for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides a comprehensive review of the market trends, drivers, barriers, key company profiles including its business and product developments.

Alpha Antitrypsin Deficiency is the most common hereditary disorder in which body is unable to produce the sufficient amount of Alpha-Antitrypsin (AAT) protein. Alpha-Antitrypsin (AAT) protein plays an important role in protecting organs of the body such as liver and lungs from the harmful effects of proteolytic enzymes such as neutrophil elastase.

The AATD market for 6MM (Japan excluded) was found to be USD 954.66 Million in 2016 and is expected to reach USD XXX Millions in 2023. We have covered PiSS, PiSZ and PiZZ deficient phenotypes as sub-segments in our epidemiology forecast. According to DelveInsight, it is estimated that these allele combinations (population at risk) is expected to increase with the CAGR of 0.60% during the period 2013-2023. Key Players like Grifols, Kamada, Shire, CSL Behring & LFB Biotechnology has already got the marketed drugs, whereas Kamada is coming up inhaled therapy for AAP deficiency.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Alpha Antitrypsin Deficiency market.

Organize sales and marketing efforts by identifying the best opportunities for Alpha Antitrypsin Deficiency in US, European Union 5 (EU5- Germany, Spain, Italy, France and the United Kingdom) and Japan.

To understand the future market competition in the global Alpha Antitrypsin Deficiency market and Insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

The Report also covers the detailed global historical and forecasted Alpha Antitrypsin Deficiency market covering United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

About DelveInsight

DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.

DelveInsight business research,

A20, Sector 7, Near to Maxfort. School, Dwarka

New Delhi-110077, India

Tel: +91-11-4568 9769 | +91 9650213330

This release was published on openPR.